Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
Stock Information for Selecta Biosciences Inc.
Loading
Please wait while we load your information from QuoteMedia.